The addition of niraparib to abiraterone acetate and prednisone led to a benefit in overall survival vs treatment with AAP alone in patients with BRCA1/2-mutated metastatic castration-resistant prostate cancer.
Previously some of the trial's results were published in two peer-reviewed abstracts and a poster at the ASCO conference in June 2022 with additional results expected to be published in scientific journals and presented in scientific forums in the future.